Document is current
Any future updates will be listed below
-
Authors
Puyén, Zully M.
Santos-Lázaro, David
Vigo, Aiko N.
Coronel, Jorge
Alarcón, Miriam J.
Cotrina, Vidia V.
Moore, David A. J.
-
Funding
Funding for this research was provided by:
Dirección de Investigación, Universidad Peruana de Ciencias Aplicadas (A-055-2021-2)
Prociencia - Instituto Nacional de Salud (230-2018-FONDECYT, 230-2018-FONDECYT, 230-2018-FONDECYT)
Newton Fund Institutional Links (414591184 Moore PER)
Wellcome Trust/Newton Fund–MRC Collaborative (200205/Z/15/Z to CRyPTIC)
Bill and Melinda Gates Foundation (OPP1133541 to CRyPTIC)
- License Information
-
More Information
Article History
Received: 29 April 2022
Accepted: 26 July 2022
First Online: 24 August 2022
Declarations
:
: The Institutional Research Ethics Committee from the INS approved the study (Reference: OC-020-19). Additionally, the CRyPTIC associated study [] (for which the objective was identification of the genomic determinants of MTB drug resistance by WGS) was reviewed and approved by the Research Ethics Committees of the INS, UPCH and LSHTM institutions. The study did not involve human samples so no informed consent was required. Instead, the study included MTB strains stored in the culture bank of the LRNM culture bank of the INS. The specific permission to use the preserved MTB strains was obtained from the National Centre for Public Health of the INS.
: Not applicable.
: The authors declare that they have no competing interests.
